LSP Closes Mega Life Sciences Fund For Europe, But US Still Way Ahead
Family Offices And Pharma Commit Funding
A new life sciences fund, LSP 6, is one of the largest fundraisings in Europe in the sector, and will invest in around 15-to-18 pharma or medtech companies.
You may also be interested in...
Global investors back Paris-headquartered Sofinnova to recoup investment in life science start-ups.
The Series A financing positions Alizé to take a rival to Shire’s Natpara through to clinical proof of concept over the next few years.
With its WPLS-IV fund now fully committed, Wellington Partners has returned to the market and raised €210m in its WPLS-V fund which will focus on European biotech and medtech opportunities.